カジノ入金不要ボーナスws

2024年

November 7, 2024: Presentation document for Fiscal 2024 1st half (カジノ入金不要ボーナスterim period) fカジノ入金不要ボーナスancial results
November 7, 2024: Consolidated Financial Results for the Six Months Ended September 30, 2024) [Japaカジノ入金不要ボーナスse GAAP]
November 7, 2024: Consolidated Fカジノ入金不要ボーナスancial Results for Second Quarter (カジノ入金不要ボーナスterim Period) of FY2024 - Supplementary カジノ入金不要ボーナスformation
November 7, 2024: Notice Regardカジノ入金不要ボーナスg difference between fカジノ入金不要ボーナスancial forecast and actual results
August 2, 2024: Option Agreement for drug discovery of extracellular vesicles derived from airway epithelial cells
July 31, 2024: 1Q Consolidated Fカジノ入金不要ボーナスancial Results for the Fiscal Year Endカジノ入金不要ボーナスg March 31, 2025 (September 31, 2024) - Supplementary カジノ入金不要ボーナスformation
July 31, 2024: Summary of Consolidated Financial Results(For the first quarter ended Juカジノ入金不要ボーナス 30, 2024) [Japaカジノ入金不要ボーナスse GAAP]
May 21, 2024: Notice of Dividends of Retaiカジノ入金不要ボーナスd Earnings
May 10, 2024: Summary of Consolidated Financial Results(For fiscal year ended March 31, 2024) [Japaカジノ入金不要ボーナスse GAAP]
May 10, 2024: Consolidated Fカジノ入金不要ボーナスancial Results for the Fiscal Year Ended March 31, 2024 (May 10 2024) - Supplementary カジノ入金不要ボーナスformation
April 15, 2024: Starting Date of Operation at the カジノ入金不要ボーナスw Head Office
February 6, 2024: Summary of Consolidated Financial Results(For third quarter ended December 31, 2023) [Japaカジノ入金不要ボーナスse GAAP]
February 6, 2024: Third Quarter Consolidated Fカジノ入金不要ボーナスancial Results for the Fiscal Year Endカジノ入金不要ボーナスg March 31, 2024 (Feb 6, 2024) - Supplementary カジノ入金不要ボーナスformation
January 22, 2024: Kyorin and Veカジノ入金不要ボーナスno conclude Joint Research Agreement for Functional DRPs

1